Literature DB >> 8713136

Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes.

M J Rogers1, R J Brown, V Hodkin, G M Blackburn, R G Russell, D J Watts.   

Abstract

Bisphosphonates are synthetic pyrophosphate analogues and are therapeutic inhibitors of bone resorption, although their exact mechanisms of action are unclear. Some bisphosphonates can be metabolised into non-hydrolysable ATP analogues by Dictyostelium discoideum amoebae, in a back-reaction catalysed by several Class II aminoacyl-tRNA synthetases. We have found that the same enzymes in cell-free extracts of several human cell lines are also capable of metabolising in vitro the same bisphosphonates that are metabolised by Dictyostelium. These results indicate that human cells, following drug internalisation, should be capable of metabolising certain bisphosphonates. The toxic effects of these bisphosphonates towards bone-resorbing osteoclasts may therefore be due to accumulation of non-hydrolysable ATP analogues or inhibition of aminoacyl-tRNA synthetase enzymes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8713136     DOI: 10.1006/bbrc.1996.1113

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

1.  Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro.

Authors:  Johanna Räikkönen; Julie C Crockett; Michael J Rogers; Hannu Mönkkönen; Seppo Auriola; Jukka Mönkkönen
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

2.  The cellular uptake and metabolism of clodronate in RAW 264 macrophages.

Authors:  H Mönkkönen; M J Rogers; N Makkonen; S Niva; S Auriola; J Mönkkönen
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

3.  [Biphosphonate-induced femoral stress fractures : A new problem and knowledge so far - case report].

Authors:  R Lenz; M Ellenrieder; R Skripitz; R Bader; C Pautke; W Mittelmeier; T Tischer
Journal:  Orthopade       Date:  2011-12       Impact factor: 1.087

Review 4.  Osteonecrosis of the jaws: clinicopathologic and radiologic characteristics, preventive and therapeutic strategies.

Authors:  Vassilios Vassiliou; Nikolaos Tselis; Dimitrios Kardamakis
Journal:  Strahlenther Onkol       Date:  2010-04-26       Impact factor: 3.621

5.  Clodronate exerts an anabolic effect on articular chondrocytes mediated through the purinergic receptor pathway.

Authors:  R G Rosa; K Collavino; A Lakhani; E Delve; J F Weber; A K Rosenthal; S D Waldman
Journal:  Osteoarthritis Cartilage       Date:  2014-07-17       Impact factor: 6.576

6.  Histochemical evidence of zoledronate inhibiting c-src expression and interfering with CD44/OPN-mediated osteoclast adhesion in the tibiae of mice.

Authors:  Hongrui Liu; Jian Cui; Jing Sun; Juan Du; Wei Feng; Bao Sun; Juan Li; Xiuchun Han; Bo Liu; Kimimitsu Oda; Norio Amizuka; Minqi Li
Journal:  J Mol Histol       Date:  2015-05-13       Impact factor: 2.611

7.  Clodronate acts on human osteoclastic cell proliferation, differentiation and function in a bioreversible manner.

Authors:  Raffaella Recenti; Giuseppe Leone; Lisa Simi; Marco Orfei; Pamela Pinzani; Giuseppe Pieraccini; Gloriano Moneti; Anna Maria Carossino; Alessandro Franchi; Gianluca Bartolucci; Silvia Carbonell Sala; Mauro Ginanneschi; Annalisa Tanini; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2007-05

Review 8.  γδ T cell receptor ligands and modes of antigen recognition.

Authors:  Eric Champagne
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2011-02-06       Impact factor: 4.291

9.  A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates.

Authors:  Hannu Mönkkönen; Seppo Auriola; Petri Lehenkari; Maarit Kellinsalmi; Ilmo E Hassinen; Jouko Vepsäläinen; Jukka Mönkkönen
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

10.  Bisphosphonates and cancer: what opportunities from nanotechnology?

Authors:  Giuseppe De Rosa; Gabriella Misso; Giuseppina Salzano; Michele Caraglia
Journal:  J Drug Deliv       Date:  2013-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.